Streetbeat News

Analyst Ratings

LEGN

Analysts have provided bullish ratings for Legend Biotech (NASDAQ:LEGN) in the last quarter. In the last 3 months, 11 analysts have offered 12-month price targets for Legend Biotech, with an average price target of $84.91, an increase of 10.47% from the previous average price target of $76.86.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 4:00 pm

MBIO

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Mustang Bio (NASDAQ:MBIO) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:59 pm

SAIA

B of A Securities analyst Ken Hoexter maintains a 'Buy' rating on Saia (NASDAQ:SAIA) and raises the price target from $490 to $500.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 3:55 pm

BFI

EF Hutton analyst Michael Albanese has reiterated a 'Buy' rating on BurgerFi International (NASDAQ:BFI) and maintained a price target of $2.5.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:55 pm

LRN

Barrington Research analyst Alexander Paris has reiterated an 'Outperform' rating on Stride (NYSE:LRN) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:53 pm

TTWO

Truist Securities analyst Matthew Thornton has reiterated a 'Buy' rating on Take-Two Interactive (NASDAQ:TTWO) and maintained a price target of $158.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:53 pm

TME

B of A Securities analyst Lei Zhang maintains a 'Buy' rating on Tencent Music Enter Gr (NYSE:TME) but lowers the price target from $10 to $8.8.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 3:51 pm

RSKD

Truist Securities analyst Terry Tillman has reiterated a 'Buy' rating on Riskified (NYSE:RSKD) and maintained a price target of $7.5.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:50 pm

DOC

Truist Securities analyst Michael Lewis has reiterated a 'Hold' rating on Physicians Realty Trust (NYSE:DOC) and maintained a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:49 pm

PTCT

Truist Securities analyst Barry Jonas has reiterated a 'Buy' rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $65.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:49 pm